Market Cap 701.31M
Revenue (ttm) 0.00
Net Income (ttm) -3.35M
EPS (ttm) N/A
PE Ratio 4.23
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio -2.16
Volume 361,500
Avg Vol 1,951,760
Day's Range N/A - N/A
Shares Out 72.38M
Stochastic %K 32%
Beta 2.55
Analysts Sell
Price Target $44.00

Company Profile

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases. The company's lead products candidate is the Narsoplimab (OMS721/MASP-2) for the treatment of hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); and in Phase II clinical trial to treat COVID-19 and acute respiratory distress syndrome. It also develops OMS1029 that has...

Industry: Biotechnology
Sector: Healthcare
Phone: 206 676 5000
Address:
The Omeros Building, 201 Elliott Avenue West, Seattle, United States
Smellystocks
Smellystocks Jul. 21 at 5:11 PM
$OMER absolute dogshit. I told the bulls this was headed to single digits and people laughed. Sad bulls.
0 · Reply
Fire7878
Fire7878 Jul. 21 at 5:08 PM
$OMER buying back debt now really only helps the stockholders that are looking to sell now. The holders that are looking to buy more shares are loosing an opportunity to buyin at lower prices due to slow sales ramp and regulatory set backs where the stock should be trading in the 7s as the debt holders would be forced to exit positions at moderate profit while adding liquidity at that price point rather than getting paid nearly double the fair market value.
0 · Reply
Fire7878
Fire7878 Jul. 21 at 4:49 PM
$OMER could have used the 60m in cash that was used for 30m in debt repayment in a high yield savings account to offset interest. 5% of 60 is > 9.5% of 30. (MATH ISNT HARD). There are hundreds of other opportunities to get higher returns on that money. Something obviously the debt holder know. They are forcing this sell, its not a master stroke by Greg due to under appreciated stock price opportunity. This is debt holders cashing out & derisking at above market value where there is no demand for the stock at conversion valuation Greg is paying to settle the debt. Either Greg has drunk to much of his own koolaid or he's corrupt. When the 100m milestone that they been teasing for 8 months hits, why would that move the stock valuation? Isnt it already priced in? Not really a surprise but possibly an opportunity to sell the pop.
0 · Reply
WinstonWolfff
WinstonWolfff Jul. 21 at 4:27 PM
$OMER Chief Commercial Officer The Chief Commercial Officer will lead commercial strategy and execution for YARTEMLEA. Duties will include building the field organization, prioritizing transplant centers, supporting formulary reviews, and overseeing pricing, reimbursement, distribution, patient access, forecasting, analytics, supply and launch performance. The CCO will develop sales, account-management and market plans; set launch metrics; manage specialty-pharmacy, hub and distribution partners; coordinate provider and patient education; and align commercial, medical, regulatory, manufacturing and communications teams. The role will also direct contracting, payer strategy, competitive intelligence, revenue forecasting, planning, customer insights, territory design, training, incentive compensation, lifecycle planning and risk management. The CCO will manage the interface with Novo Nordisk, alliance governance, milestone planning and communications related to Zalt’s Phase 3 development.
0 · Reply
WinstonWolfff
WinstonWolfff Jul. 21 at 4:24 PM
$OMER Chief Medical Officer The Chief Medical Officer will lead clinical development, medical affairs, pharmacovigilance and regulatory strategy. The CMO will oversee trial design and execution, regulatory submissions and agency interactions, medical education, real-world evidence, investigator engagement, publication planning and benefit-risk assessment. The role will support YARTEMLEA® through scientific materials, key-opinion-leader outreach, safety monitoring, medical-information responses, post-marketing commitments and guidance to transplant centers treating TA-TMA. The CMO will also direct evidence-generation plans, label expansion, lifecycle strategy, protocol development, advisory boards, investigator-sponsored studies and clinical support for payer and formulary reviews. The position will serve as scientific and clinical liaison to Novo Nordisk, coordinating data transfer, development planning, regulatory alignment and Phase 3 support for zaltenibart in PNH.
0 · Reply
bombastic_
bombastic_ Jul. 21 at 3:58 PM
$OMER I am betting debt repurchase will have major implications in future of this company. A big announcement coming?
0 · Reply
Rjsmall
Rjsmall Jul. 21 at 12:34 PM
$OMER im thinking you dont spend >$20MM on debt repurchase unless you know the $100MM is imminent🤷‍♂️
1 · Reply
stockpimpbot5000
stockpimpbot5000 Jul. 21 at 3:08 AM
$OMER Fookin' convertible notes.
0 · Reply
Fire7878
Fire7878 Jul. 21 at 2:00 AM
$OMER guys, the answer is the debt holder want to cash out NOW and don't want the head ache of dumping shares ton the market with no buyers at this price so Greg is helping his buddies out at the expense of retail shareholders
2 · Reply
resq1
resq1 Jul. 21 at 1:06 AM
$OMER Greg, maybe this can trigger a squeeze. When Novo delivers their $100 m just take it to. Vegas and 5x it to buy back all of the convertible debt and buy back 30-40% of the public shareholder equity https://www.businessinsider.com/fedex-saved-from-bankruptcy-with-blackjack-winnings-2014-7
0 · Reply
Latest News on OMER
Omeros Corporation Investigated by the Portnoy Law Firm

Jul 13, 2026, 2:16 PM EDT - 7 days ago

Omeros Corporation Investigated by the Portnoy Law Firm


Omeros stock crashes on regulatory setback: buy the dip?

Jun 26, 2026, 2:11 PM EDT - 24 days ago

Omeros stock crashes on regulatory setback: buy the dip?


Omeros Transcript: AGM 2026

Jun 18, 2026, 1:00 PM EDT - 4 weeks ago

Omeros Transcript: AGM 2026


Omeros trading resumes

2026-06-12T13:45:42.000Z - 5 weeks ago

Omeros trading resumes


Omeros trading halted, volatility trading pause

2026-06-12T13:35:42.000Z - 5 weeks ago

Omeros trading halted, volatility trading pause


Omeros Earnings Call Transcript: Q1 2026

May 13, 2026, 4:30 PM EDT - 2 months ago

Omeros Earnings Call Transcript: Q1 2026


Omeros Earnings release: Q1 2026

May 13, 2026, 4:30 PM EDT - 2 months ago

Omeros Earnings release: Q1 2026


Omeros Quarterly report: Q1 2026

May 13, 2026, 4:30 PM EDT - 2 months ago

Omeros Quarterly report: Q1 2026


Omeros reports Q1 adjusted EPS (24c), consensus (28c)

2026-05-13T20:27:08.000Z - 2 months ago

Omeros reports Q1 adjusted EPS (24c), consensus (28c)


Omeros Corporation Reports First Quarter 2026 Financial Results

May 13, 2026, 4:02 PM EDT - 2 months ago

Omeros Corporation Reports First Quarter 2026 Financial Results


Omeros Proxy statement: Proxy filing

Apr 30, 2026, 8:00 AM EDT - 2 months ago

Omeros Proxy statement: Proxy filing


Omeros Earnings Call Transcript: Q4 2025

Mar 31, 2026, 4:30 PM EDT - 3 months ago

Omeros Earnings Call Transcript: Q4 2025


Omeros Earnings release: Q4 2025

Mar 31, 2026, 4:30 PM EDT - 3 months ago

Omeros Earnings release: Q4 2025


Omeros Annual report: Q4 2025

Mar 31, 2026, 4:30 PM EDT - 3 months ago

Omeros Annual report: Q4 2025


Omeros reports Q4 EPS $1.22, consensus 36c

2026-03-31T20:05:48.000Z - 3 months ago

Omeros reports Q4 EPS $1.22, consensus 36c


Omeros announces first commercial sales of Yartemlea

2026-01-27T14:20:24.000Z - 6 months ago

Omeros announces first commercial sales of Yartemlea


Omeros Announces First Commercial Sales of YARTEMLEA®

Jan 27, 2026, 9:00 AM EST - 6 months ago

Omeros Announces First Commercial Sales of YARTEMLEA®


Omeros price target raised to $40 from $20 at H.C. Wainwright

2026-01-08T11:11:35.000Z - 6 months ago

Omeros price target raised to $40 from $20 at H.C. Wainwright


Omeros prices transplant complication drug at $36,000 per dose

Jan 7, 2026, 6:50 PM EST - 6 months ago

Omeros prices transplant complication drug at $36,000 per dose


Omeros Transcript: FDA Announcement

Jan 7, 2026, 4:30 PM EST - 6 months ago

Omeros Transcript: FDA Announcement


Omeros Press release: FDA Announcement

Jan 7, 2026, 4:30 PM EST - 6 months ago

Omeros Press release: FDA Announcement


Omeros trading resumes

2025-12-24T15:15:15.000Z - 7 months ago

Omeros trading resumes


Omeros trading halted, volatility trading pause

2025-12-24T15:10:19.000Z - 7 months ago

Omeros trading halted, volatility trading pause


Omeros Earnings Call Transcript: Q3 2025

Nov 13, 2025, 4:30 PM EST - 8 months ago

Omeros Earnings Call Transcript: Q3 2025


Omeros Quarterly report: Q3 2025

Nov 13, 2025, 4:30 PM EST - 8 months ago

Omeros Quarterly report: Q3 2025


Omeros Earnings release: Q3 2025

Nov 13, 2025, 4:30 PM EST - 8 months ago

Omeros Earnings release: Q3 2025


Omeros Corporation Reports Third Quarter 2025 Financial Results

Nov 13, 2025, 4:11 PM EST - 8 months ago

Omeros Corporation Reports Third Quarter 2025 Financial Results


Omeros Earnings Call Transcript: Q2 2025

Aug 14, 2025, 4:30 PM EDT - 1 year ago

Omeros Earnings Call Transcript: Q2 2025


Omeros Quarterly report: Q2 2025

Aug 14, 2025, 4:30 PM EDT - 1 year ago

Omeros Quarterly report: Q2 2025


Omeros Earnings release: Q2 2025

Aug 14, 2025, 4:30 PM EDT - 1 year ago

Omeros Earnings release: Q2 2025


Omeros Proxy statement: Proxy Filing

May 30, 2025, 8:00 AM EDT - 1 year ago

Omeros Proxy statement: Proxy Filing


Omeros Earnings Call Transcript: Q1 2025

May 15, 2025, 4:30 PM EDT - 1 year ago

Omeros Earnings Call Transcript: Q1 2025


Omeros Quarterly report: Q1 2025

May 15, 2025, 4:30 PM EDT - 1 year ago

Omeros Quarterly report: Q1 2025


Omeros Earnings release: Q1 2025

May 15, 2025, 4:30 PM EDT - 1 year ago

Omeros Earnings release: Q1 2025


Omeros Earnings Call Transcript: Q4 2024

Mar 31, 2025, 4:30 PM EDT - 1 year ago

Omeros Earnings Call Transcript: Q4 2024


Omeros Annual report: Q4 2024

Mar 31, 2025, 4:30 PM EDT - 1 year ago

Omeros Annual report: Q4 2024


Omeros Earnings release: Q4 2024

Mar 31, 2025, 4:30 PM EDT - 1 year ago

Omeros Earnings release: Q4 2024


Omeros Earnings Call Transcript: Q3 2024

Nov 13, 2024, 4:30 PM EST - 1 year ago

Omeros Earnings Call Transcript: Q3 2024


Omeros Earnings release: Q3 2024

Nov 13, 2024, 4:30 PM EST - 1 year ago

Omeros Earnings release: Q3 2024


Omeros Quarterly report: Q3 2024

Nov 13, 2024, 4:30 PM EST - 1 year ago

Omeros Quarterly report: Q3 2024


Smellystocks
Smellystocks Jul. 21 at 5:11 PM
$OMER absolute dogshit. I told the bulls this was headed to single digits and people laughed. Sad bulls.
0 · Reply
Fire7878
Fire7878 Jul. 21 at 5:08 PM
$OMER buying back debt now really only helps the stockholders that are looking to sell now. The holders that are looking to buy more shares are loosing an opportunity to buyin at lower prices due to slow sales ramp and regulatory set backs where the stock should be trading in the 7s as the debt holders would be forced to exit positions at moderate profit while adding liquidity at that price point rather than getting paid nearly double the fair market value.
0 · Reply
Fire7878
Fire7878 Jul. 21 at 4:49 PM
$OMER could have used the 60m in cash that was used for 30m in debt repayment in a high yield savings account to offset interest. 5% of 60 is > 9.5% of 30. (MATH ISNT HARD). There are hundreds of other opportunities to get higher returns on that money. Something obviously the debt holder know. They are forcing this sell, its not a master stroke by Greg due to under appreciated stock price opportunity. This is debt holders cashing out & derisking at above market value where there is no demand for the stock at conversion valuation Greg is paying to settle the debt. Either Greg has drunk to much of his own koolaid or he's corrupt. When the 100m milestone that they been teasing for 8 months hits, why would that move the stock valuation? Isnt it already priced in? Not really a surprise but possibly an opportunity to sell the pop.
0 · Reply
WinstonWolfff
WinstonWolfff Jul. 21 at 4:27 PM
$OMER Chief Commercial Officer The Chief Commercial Officer will lead commercial strategy and execution for YARTEMLEA. Duties will include building the field organization, prioritizing transplant centers, supporting formulary reviews, and overseeing pricing, reimbursement, distribution, patient access, forecasting, analytics, supply and launch performance. The CCO will develop sales, account-management and market plans; set launch metrics; manage specialty-pharmacy, hub and distribution partners; coordinate provider and patient education; and align commercial, medical, regulatory, manufacturing and communications teams. The role will also direct contracting, payer strategy, competitive intelligence, revenue forecasting, planning, customer insights, territory design, training, incentive compensation, lifecycle planning and risk management. The CCO will manage the interface with Novo Nordisk, alliance governance, milestone planning and communications related to Zalt’s Phase 3 development.
0 · Reply
WinstonWolfff
WinstonWolfff Jul. 21 at 4:24 PM
$OMER Chief Medical Officer The Chief Medical Officer will lead clinical development, medical affairs, pharmacovigilance and regulatory strategy. The CMO will oversee trial design and execution, regulatory submissions and agency interactions, medical education, real-world evidence, investigator engagement, publication planning and benefit-risk assessment. The role will support YARTEMLEA® through scientific materials, key-opinion-leader outreach, safety monitoring, medical-information responses, post-marketing commitments and guidance to transplant centers treating TA-TMA. The CMO will also direct evidence-generation plans, label expansion, lifecycle strategy, protocol development, advisory boards, investigator-sponsored studies and clinical support for payer and formulary reviews. The position will serve as scientific and clinical liaison to Novo Nordisk, coordinating data transfer, development planning, regulatory alignment and Phase 3 support for zaltenibart in PNH.
0 · Reply
bombastic_
bombastic_ Jul. 21 at 3:58 PM
$OMER I am betting debt repurchase will have major implications in future of this company. A big announcement coming?
0 · Reply
Rjsmall
Rjsmall Jul. 21 at 12:34 PM
$OMER im thinking you dont spend >$20MM on debt repurchase unless you know the $100MM is imminent🤷‍♂️
1 · Reply
stockpimpbot5000
stockpimpbot5000 Jul. 21 at 3:08 AM
$OMER Fookin' convertible notes.
0 · Reply
Fire7878
Fire7878 Jul. 21 at 2:00 AM
$OMER guys, the answer is the debt holder want to cash out NOW and don't want the head ache of dumping shares ton the market with no buyers at this price so Greg is helping his buddies out at the expense of retail shareholders
2 · Reply
resq1
resq1 Jul. 21 at 1:06 AM
$OMER Greg, maybe this can trigger a squeeze. When Novo delivers their $100 m just take it to. Vegas and 5x it to buy back all of the convertible debt and buy back 30-40% of the public shareholder equity https://www.businessinsider.com/fedex-saved-from-bankruptcy-with-blackjack-winnings-2014-7
0 · Reply
Fire7878
Fire7878 Jul. 20 at 10:43 PM
$OMER Greg basically paying 12 per share to debt holders when he can buy on the open market for less than 10. WHY?
7 · Reply
Abaco24
Abaco24 Jul. 20 at 10:42 PM
$OMER Recent 7-20-26 8-K filing: The Company completed the repurchase of approximately $14.5 million aggregate principal amount of Notes on July 20, 2026, for a total purchase price, inclusive of accrued and unpaid interest and all other obligations, of approximately $29.0 million. The Company previously disclosed the repurchase of $16.0 million principal amount of Notes pursuant to privately negotiated agreements with the same holders referenced above. In total, the Company has repurchased and retired $30.5 million aggregate principal amount of Notes. Approximately $40.3 million principal amount of Notes remains outstanding following completion of the repurchases.
0 · Reply
TwongStocks
TwongStocks Jul. 20 at 9:23 PM
$OMER SEC filing confirms that the Note repurchase announced on July 2 was closed today. https://www.sec.gov/ix?doc=/Archives/edgar/data/1285819/000143774926023886/omer20260716_8k.htm • $14.5M aggregate principal amount of Notes was purchased for a total amount of $29M. • Approximately $40.3 million principal amount of Notes remains outstanding following completion of the repurchases.
1 · Reply
resq1
resq1 Jul. 20 at 9:10 PM
$OMER less notes just announced in 8-k
0 · Reply
WinstonWolfff
WinstonWolfff Jul. 20 at 7:51 PM
$OMER Schwab rating update: In the last 4 weeks, Schwab's overall Omeros score has rebounded from 50 to 35 and is a high Marketperform and 5 points from moving into Outperform and a Buy rating. Sentiment has climbed from D to C. Growth rate: B, Quality : C, Valuation has moved up to B and Stability remains an F. Q2 estimates remain at $12.7 million and full year $68 million.
2 · Reply
hmb
hmb Jul. 20 at 7:44 PM
$OMER 200% would be like $29. Seems low
1 · Reply
resq1
resq1 Jul. 20 at 7:09 PM
$OMER Novo $100M immindent
2 · Reply
hmb
hmb Jul. 20 at 6:57 PM
$OMER we need some material news bad. Greg needs a social media person
2 · Reply
hmb
hmb Jul. 20 at 3:51 PM
$OMER should be $15 minimum.
2 · Reply
Yagger1980
Yagger1980 Jul. 20 at 2:43 PM
$OMER down she goes. Fair value $4.
3 · Reply
111ggg
111ggg Jul. 20 at 1:59 PM
$OMER back to fair value now. Hope to see much better price by year end.
1 · Reply
TwongStocks
TwongStocks Jul. 20 at 12:28 PM
$OMER YARTEMLEA is on the July CHMP agenda again. SCOPE: Re-examination request, Appointment of re-examination rapporteurs, timetable https://www.ema.europa.eu/en/documents/agenda/agenda-chmp-meeting-20-23-july-2026_en.pdf
3 · Reply